drugset
drugset / Trial / NCT05324410

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

NCT05324410 ↗

Phase 1 Completed 88 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.

Timeline

Start
2022-04-07
Primary completion
2022-11-07
Completion
2022-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-840 Unknown — Oral

Indications

inherited kidney disorder